Clinical guideline
Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol · 2022
0.4 to 2 cases per 100,000 people per yearIncidence of GIST
Studies and guidelines: Sarcoma
9 items with a structured summary · Sarcoma: the complete guide
Clinical guideline
Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up
Ann Oncol · 2021
0.8 to 0.9 cases per 100,000 people per yearIncidence of primary bone sarcomas
Clinical guideline
Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol · 2021
On average 4 to 5 cases per 100,000 people per yearIncidence of adult-type soft tissue and visceral sarcomas in Europe
Clinical trial · Phase 3
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
Lancet Oncol · 2016
HR 0.98 (95% CI 0.78–1.23)Event-free survival (MAPIE vs MAP)
Clinical trial · Phase 3
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Lancet Oncol · 2014
14.3 vs 12.8 monthsOverall survival, median (combination vs doxorubicin alone)
Clinical trial · Phase 3
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor
JAMA · 2012
HR 0.46 (95% CI 0.32–0.65)Recurrence-free survival (RFS): hazard ratio
Clinical trial · Phase 3
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group
J Clin Oncol · 2012
73% vs 65%5-year event-free survival (compressed vs standard)
Clinical trial · Phase 3
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
The Lancet · 2009
98% (95% CI 96–100) vs 83% (78–88)Recurrence-free survival at 1 year
Clinical trial
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
N Engl J Med · 2002
79 patients (53.7%)Partial response
Nothing found.